Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
40.2M
-
Shares change
-
-475K
-
Total reported value, excl. options
-
$328M
-
Value change
-
-$4.08M
-
Number of buys
-
33
-
Number of sells
-
-17
-
Price
-
$8.17
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q3 2022
71 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.2M shares
of 61.8M outstanding shares and own 65.08% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.7M shares), FMR LLC (6.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.76M shares), BlackRock Inc. (3.47M shares), Avoro Capital Advisors LLC (3.36M shares), Cormorant Asset Management, LP (2.99M shares), T. Rowe Price Investment Management, Inc. (1.92M shares), Aisling Capital Management LP (1.47M shares), Alphabet Inc. (1.46M shares), and VANGUARD GROUP INC (1.41M shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.